A double blinded, balanced, randomized, single dose, parallel group, active-controlled study to compare the pharmacokinetics of the test product GBL19 (recombinant asparaginase, Gennova Biopharmaceuticals Ltd.) with the reference product Spectrila® (Medac GmbH) at 5000 IU/m2, in healthy, adult, subjects.

Start Date25 Jun 2024

Sponsor / Collaborator

Gennova Biopharmaceuticals Ltd.

NCT06676293

/ CompletedNot ApplicableIIT

Compassionate Use of Combination Therapy with Asparaginase and Pembrolizumab in Patients with Nasopharyngeal Carcinoma

The goal of this study is to investigate the outcomes of patients with locoregionally advanced nasopharyngeal carcinoma (LA-NPC) or recurrent-metastatic nasopharyngeal carcinoma (RM-NPC) treated with a combination of immune checkpoint blockade (ICB) and asparaginase.

Start Date01 Aug 2023

Sponsor / Collaborator

Chang Gung Memorial Hospital

NCT05681260

/ RecruitingPhase 3IIT

A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children with Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)

T-cell lymphoblastic lymphoma (T-LBL) is the second most common subtype of non-Hodgkin lymphoma (NHL) in children and adolescents. With current treatment, event-free survival (EFS) rates vary between 75%
85%. Two different MTX intensification strategies are used commonly: HD-MTX with leucovorin rescue, and Capizzi-style MTX without leucovorin rescue plus PEG-ASP (C-MTX). Although superior outcome of patients with T-ALL receiving C-MTX compared with HD-MTX on the AALL0434 trial, the 2 approaches had not been compared directly in patients with T-LBL. There remains controversy on PET/CT interpretation in children with NHL. Large prospective studies in pediatric patients with T-LBL regarding PET/CT value for this is scarce. Around 1% pediatric patients with T-LBL will not achieve remission at the end of Induction (induction failure). The optimal treatment for this small subgroup is largely unclear. The BFM HR Blocks usually are applied to these patients even though the efficacy is unknown. Novel targeted therapies are needed for use. Dasatinib is identified as a targeted therapy for T-cell ALL in preclinical drug screening.

Start Date06 Feb 2023

Sponsor / Collaborator

Shanghai Children's Medical Center

[+14]

100 Clinical Results associated with Asparaginase

100 Translational Medicine associated with Asparaginase

100 Patents (Medical) associated with Asparaginase

1,561

Literatures (Medical) associated with Asparaginase

01 May 2025·PEDIATRIC BLOOD & CANCER

Higher Rates of Hypersensitivity Reactions to Calaspargase Compared With Pegaspargase: A Single Center Retrospective Review

Article

Author: Patel, Bianca ; Gao, Ang ; Winick, Naomi ; Smith, Caroline ; Zhang, Song ; Slone, Tamra ; Cox, Jessica ; McCarty, Kyra

ABSTRACT:

Background:

Asparaginase is a critical component of curative therapy for the treatment of pediatric acute lymphoblastic leukemia (ALL) and acute lymphoblastic lymphoma (LLy). Pegaspargase (PEG) increased the duration of asparagine depletion and lowered the incidence of hypersensitivity reactions (HSRs) compared with native asparaginase. When a second pegylated product, Calasparagase pegol‐mknl (Cal‐PEG) replaced PEG, we observed an increased incidence of HSR, defined as anaphylaxis or silent hypersensitivity. This led to a single center, retrospective review to determine the incidence of HSR in patients with ALL or LLy who received Cal‐PEG or PEG.

Procedure:

Electronic medical records of all patients who received at least two doses of Cal‐PEG (December 2022–December 2023) or PEG (December 2019–December 2022) were reviewed.

Result:

Overall, patients who received Cal‐PEG had a significantly increased rate of asparaginase‐related HSR compared with patients who received PEG. Twenty‐one of 44 (48%) patients receiving Cal‐PEG and 35 out of 154 (23%) of patients receiving PEG experienced Grade 3 or higher anaphylaxis, or silent hypersensitivity (p = 0.001). After 2:1 matching based on propensity scoring for confounding variables, patients who received Cal‐PEG continued to have a statistically significantly higher rates of HSR, with HSR occurring in 21 out of 44 (48%) and 26 out of 88 (30%) patients receiving Cal‐PEG and PEG, respectively (p = 0.04).

Conclusion:

The current administration of Cal‐PEG in large cooperative group trials will allow for a postmarketing exploration of the true risk of HSR and associated patient‐specific risk factors.

01 May 2025·CANCER LETTERS

Interleukin-2-inducible T-cell kinase inhibition to block NF-κB signaling exerts anti-tumor effects and enhances chemotherapy in NK/T-cell lymphoma

Article

Author: Song, Yuqin ; Wu, Jiajin ; Qi, Fei ; Mi, Lan ; Hu, Dingyao ; Cao, Jiaowu ; Ding, Ning ; Zhang, Weimin ; Xie, Yan ; Zhu, Jun ; Ye, Yingying ; Wang, Dedao ; Yu, Hui ; Li, Miaomiao ; Deng, Mi

Natural killer/T-cell lymphoma (NKTCL) is a highly aggressive non-Hodgkin lymphoma. Relapsed/refractory (R/R) NKTCL patients have dismal prognosis and lack effective treatments, novel therapeutics are urgently needed. Here we found interleukin-2-inducible T-cell kinase (ITK) expression was elevated in NKTCL cells and patient tumors. And higher ITK expression was associated with worse clinical outcomes. In vitro ITK knockdown inhibited NKTCL cell growth, induced apoptosis, cell cycle arrest and impaired its colony-forming ability while ITK overexpression accelerated cell proliferation. In vivo ITK knockdown greatly impeded lymphoma growth in mouse model, indicating it as a potential therapeutic target. Mechanistically, ITK knockdown inhibited NKTCL cell growth by attenuating oncogenic NF-κB signaling, which is revealed by transcriptomic profiling and further validated by in vitro assays and in vivo NKTCL models. Additionally, we showed that ITK inhibitors could inhibit NKTCL cell proliferation, promote apoptosis and suppressed tumor progression in NKTCL cell line-derived xenograft (CDX) model. Furthermore, we established a patient-derived xenograft (PDX) model from a NKTCL patient refractory to prior anti-PD-1 and asparaginase containing therapy. The primary cells from this patient highly expressed ITK and were responsive to ITK inhibitor. And ITK inhibitor effectively repressed tumor progression in PDX model. Finally, we found ITK inhibition improved the response of NKTCL cell lines to chemotherapy and overcome chemotherapy resistance in primary cells. Collectively, our results demonstrated that ITK served as an oncogene in NKTCL and represented a novel therapeutic vulnerability to be targeted or in combination with chemotherapy drugs for this disease.

01 Apr 2025·Clinical Lymphoma Myeloma & Leukemia

The Impact of Clinical Features on Survival and Relapse of Patients Diagnosed With T-cell Acute Lymphoblastic Leukemia – a Multicenter Cohort Study

Article

Author: Massaut, Ires Hamyra Bezerra ; Hamerschlak, Nelson ; de Carvalho, Maria Eduarda Alonso Joaquim ; Duarte, Bruno Kosa Lino ; Kerbauy, Fabio Rodrigues ; Velloso, Elvira Drp ; Rocha, Vanderson ; Batista, Renata Lyrio Rafael ; Piaia, Camila ; Aragão, Jordana Santos Ramires ; da Silva, Diego Luz Felipe ; Rego, Eduardo M ; Silva, Wellington F ; Mauad, Vitor Augusto Queiroz ; de Oliveira, Yve Cardoso ; Chapchap, Eduardo Cerello

BACKGROUND:

T-cell acute lymphoblastic leukemia (T-ALL) remains understudied compared to B-cell ALL, especially in Latin America. Different biology and response to chemotherapy have been described.

METHODS:

This retrospective multi-site cohort study analyzed data from 152 newly diagnosed T-ALL patients aged 15 years and above, between January 2010 and June 2022.

RESULTS:

The median age was 30 years, with 53.9% of the patients presenting thymic T-ALL. Asparaginase-based regimens were used in 80.5% of patients. Five-year overall survival (OS) and event-free survival (EFS) were 44.3% and 41%, respectively. Thymic (CD1a) phenotype (HR 0.50 [0.28-0.89], P = .019) and asparaginase-based regimens (HR 0.53 [0.32-0.88], P = .014) were associated with improved OS, while older age predicted inferior OS (HR 1.02, P = .017). The 60-day cumulative incidence of thrombosis was 19.5% and induction death rate of 11.2%.

CONCLUSIONS:

The study provides real-world multicenter Brazilian data on adult T-ALL, which might represent Latin America's scenario, also highlights the benefits of pediatric-inspired regimens, especially for younger adults, key prognostic factors and that awareness is needed to manage thrombotic/death risks in the early treatment phases to improve outcomes.

News (Medical) associated with Asparaginase

27 Mar 2025

·www.prnewswire.com

CalciMedica Reports 2024 Financial Results and Provides Clinical & Corporate Updates

Enrollment ongoing in Phase 2 KOURAGE trial of Auxora™ in acute kidney injury (AKI) and respiratory failure; data expected around the end of 2025 Post-hoc analysis of subset of patients with AKI in the Phase 2 CARDEA trial of Auxora in severe COVID-19 pneumonia showed a 62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with Auxora versus placebo Cash position expected to fund operations into mid-2026 LA JOLLA, Calif., March 27, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today reported financial results for the year ended December 31, 2024 and provided clinical and corporate updates. "Enrollment in our Phase 2 KOURAGE trial is on track to deliver data around the end of 2025," said Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. "Looking ahead to the KOURAGE readout, we are further encouraged by the promising readthrough from the data recently presented at the 30th International AKI & CRRT Conference, which show a 62.7% relative reduction in mortality in CARDEA patients with both kidney failure and respiratory failure, mirroring KOURAGE's patient population. With the proceeds from our recent credit facility with Avenue Capital, we have ample runway to get through our KOURAGE data readout based on our current enrollment projections and engage with the FDA on the design of a Phase 3 program in acute pancreatitis with SIRS in the next few months." Recent Clinical & Corporate Highlights: Clinical Updates & Anticipated Milestones Acute Kidney Injury (AKI) Program Update Enrollment ongoing in Phase 2 KOURAGE trial: Enrollment is ongoing in KOURAGE, the Company's randomized, double-blind, placebo-controlled Phase 2 trial of Auxora™ in patients with severe AKI with associated acute hypoxemic respiratory failure (AHRF). CalciMedica expects to enroll 150 patients with stage 2 and stage 3 AKI who have AHRF and are receiving oxygen either by non-invasive mechanical ventilation, high-flow nasal cannula, or invasive mechanical ventilation. Data are expected around the end of 2025. Post-hoc analysis of patients with AKI from the Phase 2 CARDEA trial in severe COVID-19 pneumonia: In March 2025, Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica, delivered a plenary presentation at the 30th International Acute Kidney Injury and Continuous Renal Replacement Therapy (AKI & CRRT) Conference. The presentation outlined the multi-faceted role of CRAC channels in AKI pathophysiology as well as new data based on a post-hoc analysis from the previously completed CARDEA trial, which included 38 patients who were enrolled with AKI in addition to respiratory failure. Within this subset: Patients treated with Auxora showed a 62.7% relative reduction and 29.3% absolute reduction versus placebo in mortality at day 30 which persisted through day 60. 7 out of 15 (46.7%) patients on placebo died by day 30 and day 60 as compared to 4 out of 23 (17.4%) patients on Auxora. Acute Pancreatitis (AP) Program Update End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) planned: CalciMedica plans to hold an end-of-Phase 2 meeting with the FDA around the middle of 2025 and expects to be in a position to initiate a Phase 3 program in AP and accompanying systemic inflammatory response syndrome (SIRS) around the end of 2025 pending additional funding. Plenary presentation delivered by a collaborator at the American Pancreatic Association (APA) 2024 Annual Meeting: CalciMedica collaborator Prof. Robert Sutton, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, delivered a plenary presentation titled "Auxora Decreases the Development of Severe Organ Failure in Patients with Acute Pancreatitis and SIRS" at the APA 2024 Annual Meeting. Asparaginase-induced Pancreatic Toxicity (AIPT) Program Update Enrollment ongoing in Phase 2 portion of CRSPA trial: Enrollment is ongoing in the Phase 2 portion of the Company's CRSPA study in AIPT, with over 50% of the study enrolled. CalciMedica expects to provide an update on this study in the second half of 2025. Corporate Updates Leadership team strengthened with CFO appointment: In November 2024, CalciMedica announced the appointment of Stephen Bardin as Chief Financial Officer and the previously planned departure of Daniel Geffken, Interim Chief Financial Officer. Mr. Bardin has extensive experience in capital raising, corporate development, and strategic finance, and most recently served as Chief Financial Officer of atai Life Sciences. Prior to atai, he was Senior Vice President of Finance and Operations at BridgeBio. Key addition to Board of Directors: In January 2025, the Company announced the appointment of Alan Glicklich, M.D., to the Company's Board of Directors. Dr. Glicklich has more than 20 years of experience in the biotechnology industry and currently serves as Chief Medical Officer of Nuvig Therapeutics. Previously, he was Chief Medical Officer of Chinook Therapeutics. Other Business Highlights: On March 5, 2025, CalciMedica announced a credit facility with Avenue Venture Opportunities Fund II, L.P., a fund of Avenue Capital Group, providing up to $32.5 million. The credit agreement, which has a term of 3.5 years, includes an initial tranche of $10 million fully funded at close and additional tranches of up to $22.5 million available to the Company subject to certain milestones. 2024 Financial Results: Cash Position: Cash, cash equivalents, and short-term investments were $18.7 million as of December 31, 2024, which, combined with the net proceeds of $9.7 million from the Company's recent debt financing announced in March 2025, the Company expects to be sufficient to fund its current operating plan into mid-2026. R&D Expenses: Research and development expenses were $14.5 million for the year ended December 31, 2024, compared to $15.9 million for the year ended December 31, 2023. The decrease of $1.4 million was primarily related to a decrease in personnel expense of $3.3 million, driven by one-time charges as a result of the merger with Graybug Vision ("Merger") for the year ended December 31, 2023. This was partially offset by an increase of $1.3 million in chemistry, manufacturing, and control activities related to the Company's Phase 2 clinical trials of Auxora, costs related to preclinical studies of $0.3 million, and consultants and other costs of $0.3 million. G&A Expenses: General and administrative expenses were $9.7 million for the year ended December 31, 2024, compared to $22.2 million for the year ended December 31, 2023. The decrease of $12.5 million was primarily related to a decrease in personnel expense of $13.0 million, driven by one-time charges as a result of the Merger for the year ended December 31, 2023. Additionally, professional services decreased $0.2 million due to increased costs related to the Merger for the year ended December 31, 2023. These costs were partially offset by an increase of $0.7 million in consultants and other costs. Other Income: Other income for the year ended December 31, 2024, was $10.5 million, compared to $3.7 million for the year ended December 31, 2023. The increase of $6.8 million was due to the fair value adjustments to CalciMedica's warrant liability of $9.5 million as a result of the 2024 Private Placement, compared to fair value adjustments to its warrant liability and convertible promissory notes for the year ended December 31, 2023, and due to an increase of $0.4 million of interest income on the Company's cash equivalents and short-term investments for the year ended December 31, 2024, as compared to the year ended December 31, 2023. Net Loss: Net loss was $13.7 million for the year ended December 31, 2024, compared to a net loss of $34.4 million for the year ended December 31, 2023. About CalciMedica CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) with data expected around the end of 2025 and continuing to support the ongoing investigator-initiated Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT) with an update expected in the second half of 2025. CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit . Forward-Looking Statements This communication contains forward-looking statements which include, but are not limited to, CalciMedica's expected cash runway; CalciMedica's planned and ongoing clinical trials and the timing, design, expected patient enrollment thereof and the expected timing for the release of data from those trials, including its Phase 2 KOURAGE trial of Auxora in AKI with associated AHRF; its ongoing Phase 1/2 CRSPA trial of Auxora in pediatric patients with AIPT; plans for an end-of-Phase 2 meeting with the FDA for CARPO and to be in a position to initiate a pivotal trial in AP around the end of 2025; the potential benefits of Auxora for the treatment of AP, AKI and AIPT; the potential of CalciMedica's proprietary technology to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases; and the potential of additional proceeds from the credit facility with Avenue Capital Group if certain milestones are achieved. These forward-looking statements are subject to the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. CalciMedica's expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks, and changes in circumstances, including but not limited to risks and uncertainties related to: the impact of fluctuations in global financial markets on CalciMedica's business and the actions it may take in response thereto; CalciMedica's ability to execute its plans and strategies; the ability to obtain and maintain regulatory approval for Auxora; results from clinical trials or preclinical studies may not be indicative of results that may be observed in the future; potential safety and other complications from Auxora; the scope, progress and expansion of developing and commercializing Auxora; the size and growth of the market therefor and the rate and degree of market acceptance thereof; economic, business, competitive, and/or regulatory factors affecting the business of CalciMedica generally; CalciMedica's ability to protect its intellectual property position; the impact of government laws and regulations; and CalciMedica's financial position and need for additional capital. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption "Risk Factors" in CalciMedica's Annual Report on Form 10-K for the year ended December 31, 2024, being filed with the Securities and Exchange Commission (SEC) later today, and elsewhere in CalciMedica's subsequent reports on Form 10-K, Form 10-Q or Form 8-K filed with the SEC from time to time and available at . These documents can be accessed on CalciMedica's web page at ir.calcimedica.com/financials-filings/sec-filings. The forward-looking statements contained herein are made as of the date hereof, and CalciMedica undertakes no obligation to update them after this date, except as required by law. Contact Information Argot Partners Sarah Sutton/Kevin Murphy [email protected] (212) 600-1902 SOURCE CalciMedica, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 2Financial StatementExecutive ChangeClinical Result

04 May 2022

·www.biospace.com

Jazz Adds Narcolepsy Pact with Sumitomo, Sees Clear Ahead to Vision 2025

For Jazz Pharmaceuticals, 2022 is off to a roaring start, building on its Vision 2025 plan announced earlier this year that includes a key licensing deal with Werewolf Therapeutics and another announced Wednesday with Japan’s Sumitomo Pharma Co. for a narcolepsy treatment. With its focus on neuroscience and oncology, the company is on a clear path to hitting its goal of achieving $5 billion in annual revenue by 2025. In a late-afternoon conference call, Jazz Chief Executive Officer Bruce Cozadd said the leadership team is extremely pleased with the company’s direction since announcing the Vision 2025 plan. “In short, we’re really pleased with where the business is and where the business is going,” Cozadd told journalists and analysts on the call as the company highlighted its first quarter financial results. For Q1, Jazz Pharma saw total revenue of $813.7 million, an increase of 34% compared to the same period of time in 2021. Those sales were powered by $612.1 million in neuroscience, driven by sales of epilepsy drug Epidiolex and $433.6 million from Xywav, a low-sodium treatment option for both cataplexy and excessive daytime sleepiness in people living with narcolepsy. Cozadd said the company has been extremely encouraged by the ongoing launch of Xywav and has seen an increase in prescribers turning to the medication. The growth potential for Xywav is expected to be about $2 billion in annual revenue. In addition to Xywav, Cozadd pointed to the ongoing success with Rylaze, a leukemia drug approved by the U.S. Food and Drug Administration last year. Rylaze was approved for patients who have developed hypersensitivity to E. coli-derived asparaginase, an enzyme that is a common component of the chemotherapy regimen used for leukemia patients. Currently, the medication requires dosing every 48 hours but earlier this year, Jazz submitted a supplemental Biological License Application that would allow dosing on a Monday, Wednesday, Friday intramuscular dosing schedule, as well as an sBLA for intravenous administration. Both sBLAs are being reviewed by the FDA under the Real-Time Oncology Review (RTOR) program. Additionally, the company in-licensed two assets that Robert Iannone, global head of research and development at Jazz, said offer the company exciting possibilities in areas of core interest. The first asset, brought in from Werewolf, is an engineered IFN⍺2b cytokine pro-drug that gave Jazz its first immuno-oncology program. Now known as JZP898, the compound has demonstrated anti-tumor activity in preclinical models and Iannone suggested in a previous interview that it has the potential to complement a number of currently utilized oncology treatments. The other newly-licensed asset is Sumitomo’s DSP-0187, a potent and highly selective oral orexin-2 receptor agonist, now known as JZP441. Iannone said the experimental therapeutic has potential applications for the treatment of narcolepsy, idiopathic hypersomnia and other sleep disorders, which “further strengthens our leadership in sleep medicine.” Cozadd added that the licensing agreements expand the company’s pipeline in core therapeutic areas and remain consistent with its strategy. “Our three recent transactions are aligned with our broader strategy, allowing us to focus on our highest priorities, enhance our pipeline in areas of key interest in neuroscience and oncology and drive long-term shareholder value,” he said. Another key move for Jazz this quarter was the divestiture of narcolepsy drug Sunosi to Axsome Therapeutics in March. The company sold the medication for $53 million in upfront payments plus royalties. Cozadd said the move was strategic, allows increased investment opportunities and sharpens the company’s focus on the highest strategic priorities. On the oncology side of the house, Zepzecala (lurbinectedin), which has been approved for the treatment of small cell lung cancer, generated $59 million for the quarter, a 9% increase. Jazz said it is pleased that Zepzecala has become the “treatment of choice” in the second line for SCLC only 18 months after it was approved by the FDA. Earlier this year, Jazz enrolled the first patient in its EMERGE 201 study, which will assess Zepzecala as a monotherapy in various solid tumors. Jazz hopes that Zepzecala, an alkylating drug that binds guanine residues within DNA, will prove to be safe and effective in different solid tumor types, including urothelial carcinoma, large cell neuroendocrine carcinoma of the lung and homologous recombination deficient tumors. Looking ahead, Jazz is anticipating data from a Phase III study of nabiximols in multiple sclerosis later this year that could lead to a New Drug Application by the end of 2022.

Jazz Pharmaceuticals, Inc.NarcolepsyFinancial StatementLicense out/in

100 Deals associated with Asparaginase

External Link

KEGG	Wiki	ATC	Drug Bank
D02997	Asparaginase	L01XX02	DB00023

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	European Union	medac Gesellschaft für klinische Spezialpräparate mbH	14 Jan 2016
Acute Lymphoblastic Leukemia	Iceland	medac Gesellschaft für klinische Spezialpräparate mbH	14 Jan 2016
Acute Lymphoblastic Leukemia	Liechtenstein	medac Gesellschaft für klinische Spezialpräparate mbH	14 Jan 2016
Acute Lymphoblastic Leukemia	Norway	medac Gesellschaft für klinische Spezialpräparate mbH	14 Jan 2016

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Burkitt Lymphoma	Phase 2	Brazil	medac Gesellschaft für klinische Spezialpräparate mbH	26 Apr 2019
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma	Phase 2	Brazil	Medac SrL	26 Apr 2019
Pre B-cell acute lymphoblastic leukemia	Phase 2	Germany	medac Gesellschaft für klinische Spezialpräparate mbH	01 Jul 2009
Pre B-cell acute lymphoblastic leukemia	Phase 2	Netherlands	medac Gesellschaft für klinische Spezialpräparate mbH	01 Jul 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EHA2024	Not Applicable	Acute Lymphoblastic Leukemia	502	Asparaginase (Hematology/Oncology Specialists)	zvxxvexsfq(msyjqnahrt) = krzhkacsry krevfdgjqb (uvqckxvxqe )	Negative	14 May 2024
EHA2024	Not Applicable	Ph-Like Acute Lymphoblastic Leukemia	43	PEG-ASP	glhndggivo(oyhcvsymva) = bhtdypvoay ewfcxuwdyx (dktdqpqtzh )	-	14 May 2024
EHA2024	Not Applicable	asparaginase	151	NEA	hzwsnoembz(zdziirmhaw) = kedfrnwhbd etyiyftgzc (ncqppumzga )	Positive	14 May 2024
				PEG	hzwsnoembz(zdziirmhaw) = zvikugbbzp etyiyftgzc (ncqppumzga )
EHA2023	Not Applicable	Acute Lymphoblastic Leukemia	-	Venetoclax-based regimen	sbvcanpndc(zdgqyobvyx) = ynwfjbeixw iuikxladfg (pibkgkzhxu ) View more	-	08 Jun 2023
NCT01371981 (AAML1031, CTgov)	Phase 3	Acute Myeloid Leukemia \| Myeloid Tumor \| Myeloid Sarcoma	1,645	Quality-of-Life Assessment+Etoposide+Mitoxantrone Hydrochloride+Asparaginase+Cytarabine+Daunorubicin Hydrochloride (Arm A)	pmgxakfnlf = kxzfwxuicg uyqyxyutbs (cewxcflier, rifovekyrv - deisajpgxy) View more	-	07 Jul 2020
				Quality-of-Life Assessment+Etoposide+Mitoxantrone Hydrochloride+Asparaginase+bortezomib+Cytarabine+Daunorubicin Hydrochloride (Arm B)	pmgxakfnlf = luaeyjdpkb uyqyxyutbs (cewxcflier, faxngrntoj - vcaketgwnf) View more
EHA2020	Not Applicable	Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia	-	Asparaginase-containing chemotherapy	bphxvxyiyg(uxxzoboypu) = oqrivpmuxy xxmlpzqezu (ldffiardwy ) View more	Positive	14 May 2020
EHA2017	Not Applicable	Acute Lymphoblastic Leukemia	35	BFM-based protocol	bnpfjypjyk(gwklxayzpx) = egzwupzcgn vvzwefnpiu (fuorqwgfrw )	-	18 May 2017
				GMALL-based protocol	bnpfjypjyk(gwklxayzpx) = yjnpsmrpvt vvzwefnpiu (fuorqwgfrw )
NCT00372593 (AAML0531, CTgov)	Phase 3	Acute Myeloid Leukemia	1,070	etoposide+asparaginase+cytarabine+mitoxantrone hydrochloride+daunorubicin hydrochloride (Arm A: Standard Arm - No GMTZ, AML Pts w/Out Down Syndrome)	sswjoxwftn = hmecojipcb xziyqmekoa (ohpykksnky, dzqnsekqpt - erexvsbfmb) View more	-	13 Jan 2015
				etoposide+gemtuzumab ozogamicin+asparaginase+cytarabine+mitoxantrone hydrochloride+daunorubicin hydrochloride (Arm B: Experimental - With GMTZ, AML Pts w/Out Down Syndrome)	sswjoxwftn = mzgvpcflgv xziyqmekoa (ohpykksnky, wsovpgzeoz - nzehnczghr) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis